NCT02718443已完成1 期
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma to Examine Safety, Tolerability, Immune and Biomarker Response to the Investigational VEGFR-2 DNA Vaccine VXM01
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Vaximm GmbH
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Safety and tolerability taking into account treatment-limiting toxicities (TLTs)
研究概览
简要总结
VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent, signed and dated
- •Histologically diagnosed intracranial supratentorial malignant glioma (contrast-enhancing anaplastic astrocytoma WHO Grade III or glioblastoma WHO Grade IV).
- •Male or female patients who must be post-menopausal for at least 2 years or surgically sterile.
- •Age ≥18 years
- •Evidence of tumor progression following at least one therapy regimen that must have contained radiation and chemotherapy with temozolamid, as measured by MRI
- •Candidates for a tumor reoperation
- •Neurosurgical intervention should be postponable for 30 days
- •Laboratory results (clinical chemistry, hematology, urine, liver enzymes, creatinine) without clinically relevant abnormalities
- •Patients must be able to undergo MRI
- •No concomitant medication with dexamethasone at the time of vaccination
- •No active infection at the time of vaccination
- •Karnofsky performance status >70
- •Appropriate hematologic parameters (for immunomonitoring): leukocytes ≥4.0 x 109 / L, lymphocytes ≥0.6 x 109 / L
- •Tumor samples available for pathology review, central detection of T-cell responses in the peripheral blood and in the tumor tissue
- •No medical or social conditions that may interfere with study outcome and follow-up
排除标准
- •Treatment in any other clinical trial within 30 days before screening
- •Known positive test results for Hepatitis B surface antigen , hepatitis C virus antibodies, human immunodeficiency virus antibodies -1/-2
- •Any other condition or treatment that, in the opinion of the investigator, might interfere with the study or current drug or substance abuse
- •Inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study
- •Unlikely to comply with the protocol requirements, instructions and study-related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study
- •Pregnancy or breast feeding
- •Positive for anti-typhoid IgG/IgM antibodies according to the onsite test on Day 0
- •Cardiovascular disease defined as:
- •Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)
- •Arterial thromboembolic event within 6 months before randomization including:
- •Myocardial infarction
- •Unstable angina pectoris
- •Cerebrovascular accident
- •Transient ischemic attack
- •Congestive heart failure New York Heart Association grade III to IV
- •Serious ventricular arrhythmia requiring medication
- •Clinically significant peripheral artery disease > grade 2b according to Fontaine
- •Intracranial ischemic stroke within 6 months before randomization
- •History of intracranial hemorrhage
- •Hemoptysis within 6 months before randomization
- •Esophageal varices
- •Upper or lower gastrointestinal bleeding within 6 months before inclusion (Day 0)
- •Significant traumatic injury or surgery within 4 weeks before randomization
- •Non-healing wound, incomplete wound healing, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion
- •Gastrointestinal fistula
- •Thrombolysis therapy within 4 weeks before randomization
- •Presence of any acute or chronic systemic infection
- •Major surgical procedures, or open biopsy within 4 weeks before randomization
- •Chronic concurrent therapy within 2 weeks before and during the treatment period up to Day 35 with:
- •Corticosteroids (except steroids for adrenal failure or emesis prophylaxis up to 4 mg daily dose) or immunosuppressive agents
- •Antibiotics
- •Bevacizumab
- •Any cancer anti-angiogenic treatment
- •Chemotherapy from screening until reoperation (Day 35)
- •Known multi-drug resistant gram-negative germ
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications
- •Women of childbearing potential
- •Any condition which results in an undue risk for the patient during the study participation according to the investigator
研究组 & 干预措施
VXM01
Experimental
VXM01 10E6 or 10E7 CFU
干预措施: VXM01 (Drug)
结局指标
主要结局
Safety and tolerability taking into account treatment-limiting toxicities (TLTs)
时间窗: 12 months
AEs listed together with information on onset, duration, severity, seriousness, relationship to the study drug, relationship to chemotherapy and to the underlying disease, outcome, and action taken. Frequency tables by System Organ Class and preferred term.
次要结局
- Immune Response by Enzyme Linked Immuno Spot (ELISpot)(12 months)
- Serum biomarker Response by Enzyme Linked Immuno Sorbent Assay (ELISA)(12 months)
- Vascular normalization index (VNI) including tumor perfusion acc. to Sorensen 2009(12 months)
- Tumor immune cell infiltration by tumor tissue immunohistochemistry(35 days)
- Tumor response or progression on MRI acc. to Response Assessment in Neuro-Oncology (RANO) criteria(12 months)
- Clinical Response including time to progression, progression free survival, overall survival(12 months)
- Biodistribution and shedding of VXM01 bacteria(10 days)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent GlioblastomaRecurrent GlioblastomaNCT05324501Biodexa Pharmaceuticals4
终止
不适用
Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORTRecurrent GBMGlioblastomaGBMNCT04763031Parkridge Medical Center1
终止
1 期
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid TumorsSolid Tumors, AdultMultiple MyelomaLymphomaNCT05698888Virtuoso BINco, Inc.2
终止
1 期
Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19Covid19NCT04884295ExeVir Bio BV27
招募中
3 期
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 DiabetesImpaired Hypoglycemic AwarenessSevere HypoglycemiaDiabetes Mellitus, Type 1NCT04786262Vertex Pharmaceuticals Incorporated57